ProCE Banner Activity

CME

The Evolving Role of Immune Checkpoint Inhibitors in the Multidisciplinary Management of Bladder Cancer

Multimedia
This 3-part video series provides expert insights and practical guidance on the multidisciplinary approach to immunotherapy for the treatment of patients with urothelial cancer for urologists and medical oncologists.

Physicians : maximum of 1.00 AMA PRA Category 1 {Credit}

Released: August 22, 2018

Expiration: August 21, 2019

No longer available for credit.

Share

Faculty

David Y. T. Chen

David Y. T. Chen, MD, FACS

Associate Professor, Urologic Oncology
Department of Surgical Oncology
Director, Urologic Oncology Fellowhip
Fox Chase Cancer Center-Temple Health
Philadelphia, Pennsylvania

Alexander Kutikov

Alexander Kutikov, MD, FACS

Chief of Urology and Urologic Oncology
Professor of Urologic Oncology
Department of Surgical Oncology
Fox Chase Cancer Center
Temple University Health System
Philadelphia, Pennsylvania

Elizabeth Plimack

Elizabeth Plimack, MD, MS

Assistant Professor
Associate Member
Medical Oncology
Fox Chase Cancer Center
Philadelphia, Pennsylvania

Provided by

Provided by Postgraduate Institute for Medicine
ProCE Banner

Supporters

This activity is supported by an educational grant from

Merck Oncology

Target Audience

This program is intended for urologists, medical oncologists, and other healthcare providers who care for patients with bladder cancer.

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Discuss newer or emerging therapies for bladder cancer
  • Describe the impact of immune checkpoint inhibitors on therapeutic plans and agent sequencing for bladder cancer
  • Incorporate patient preferences and goals, along with clinical data, when planning treatment for bladder cancer
  • Facilitate physician collaboration and referrals among urologists, medical oncologists, and urologic oncologists when treating patients with bladder cancer
  • Identify patients who are eligible to enroll on ongoing clinical trials of immune checkpoint inhibitors

Disclosure

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Faculty Disclosure

Primary Author

David Y. T. Chen, MD, FACS

Associate Professor, Urologic Oncology
Department of Surgical Oncology
Director, Urologic Oncology Fellowhip
Fox Chase Cancer Center-Temple Health
Philadelphia, Pennsylvania

David Y. T. Chen, MD, FACS, has disclosed that he has ownership interest in Pfizer.

Alexander Kutikov, MD, FACS

Chief of Urology and Urologic Oncology
Professor of Urologic Oncology
Department of Surgical Oncology
Fox Chase Cancer Center
Temple University Health System
Philadelphia, Pennsylvania

Alexander Kutikov, MD, FACS, has no real or apparent conflicts of interest to report.

Elizabeth Plimack, MD, MS

Assistant Professor
Associate Member
Medical Oncology
Fox Chase Cancer Center
Philadelphia, Pennsylvania

Elizabeth R. Plimack, MD, MS, has disclosed that she has received consulting fees from AstraZeneca, Bristol-Myers Squibb, Clovis, Exelixis, Genentech, Merck, and Pfizer and funds for research support from Astellas, AstraZeneca, Bristol-Myers Squibb, Genentech, Merck, Peloton, and Pfizer.

Staff Disclosure

Staff

Krista Marcello,

Associate Managing Editor

Krista Marcello has no real or apparent conflicts of interest to report.

Megan K. Murphy, PhD

Scientific Director

Megan K. Murphy, PhD, has no real or apparent conflicts of interest to report.

Kevin Obholz, PhD

Editorial Director, Hematology/Oncology

Kevin Obholz, PhD, has no real or apparent conflicts of interest to report.

Timothy A. Quill, PhD

Senior Managing Editor

Timothy A. Quill, PhD, has no real or apparent conflicts of interest to report.

Kristen Rosenthal, PhD

Clinical Editor

Kristen M. Rosenthal, PhD, has no real or apparent conflicts of interest to report.

Instructions for Credit

Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Clinical Care Options, LLC.  Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Additional Information

Participation in this self-study activity should be completed in approximately 1 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from August 22, 2018, through August 21, 2019:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Program Medium

This program has been made available online.


Goal


The goal of this activity is to improve participants’ understanding of the role of immune checkpoint inhibitors for bladder cancer and establish an efficient infrastructure to support physician collaboration and timely, more prevalent referrals among urologists and medical oncologists.